India, Aug. 1 -- image credit- freepik

Drug safety has come under renewed scrutiny as regulators in India and overseas step up surveillance beyond manufacturing compliance. Within weeks, Lupin's recall of more than 2.5 million bottles of an ophthalmic product in the United States, Maharashtra Food and Drug Administration's action against Cadila Pharmaceuticals' Aciloc products, and the Central Drugs Standard Control Organisation's (CDSCO) latest quality alerts have underscored the growing focus on contamination, medication errors and post-market surveillance.

The latest action comes from the United States, where Lupin Pharmaceuticals, the US subsidiary of Lupin Limited, voluntarily recalled 2,530,182 bottles of Prednisolone Acetate Opht...